Chronic active Epstein-Barr virus infection progresses to aggressive NK cell leukemia with a poor prognosis.
暂无分享,去创建一个
Yang Yang | Liting Chen | L. Sheng | M. Zheng | Xiangrong Hu | Yuhan Bao | Yuling Wan
[1] P. Brousset,et al. Epstein–Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features , 2021, Cancers.
[2] J. Xiong,et al. Inherited Genetic Susceptibility to Nonimmunosuppressed Epstein-Barr Virus-associated T/NK-cell Lymphoproliferative Diseases in Chinese Patients , 2021, Current Medical Science.
[3] C. Shannon-Lowe,et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. , 2021, Blood.
[4] C. Münz. Redirecting T Cells against Epstein–Barr Virus Infection and Associated Oncogenesis , 2020, Cells.
[5] L. Weiss,et al. EBV-Associated Lymphoproliferative Disorders: Update in Classification. , 2019, Surgical pathology clinics.
[6] H. Kimura,et al. Editorial: Epstein-Barr Virus-Associated T/NK-Cell Lymphoproliferative Diseases , 2019, Front. Pediatr..
[7] K. Nevel,et al. Central Nervous System Involvement of Natural Killer and T Cell Neoplasms , 2019, Current Oncology Reports.
[8] H. Kimura,et al. Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases , 2019, Front. Pediatr..
[9] A. Arai. Chronic active Epstein–Barr virus infection: a bi-faceted disease with inflammatory and neoplastic elements , 2018, Immunological medicine.
[10] L. Weiss,et al. Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update. , 2018, Human pathology.
[11] T. Koyama,et al. STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target , 2018, Oncotarget.
[12] W. Chan,et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target , 2018, Nature Communications.
[13] J. Cohen,et al. Chronic Active Epstein–Barr Virus Disease , 2017, Front. Immunol..
[14] Shaoping Ling,et al. Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes , 2017, Blood Cancer Journal.
[15] Sonali M. Smith,et al. Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] P. Khong,et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. , 2017, Blood.
[17] K. Kawa,et al. How we treat chronic active Epstein–Barr virus infection , 2017, International Journal of Hematology.
[18] T. Murata,et al. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells , 2016, Oncotarget.
[19] Y. Ko,et al. l-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia , 2016, Journal of Hematology & Oncology.
[20] L. Huebsch,et al. A relapsed aggressive NK‐cell leukemia with CNS involvement diagnosed by cerebrospinal fluid examination , 2016, Diagnostic cytopathology.
[21] M. Du,et al. Aggressive natural killer-cell neoplasm presenting in the marrow: a report of two cases including one with gains of chromosomes 4q and 9p , 2015, Diagnostic Pathology.
[22] A. Fischer,et al. LYST Controls the Biogenesis of the Endosomal Compartment Required for Secretory Lysosome Function , 2015, Traffic.
[23] Liang-ding Hu,et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. , 2014, Blood.
[24] Danmei Xu,et al. Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia. , 2014, Translational research : the journal of laboratory and clinical medicine.
[25] T. Murata,et al. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein–Barr virus-associated T cell and natural killer cell lymphoma , 2014, Cancer science.
[26] J. Ouyang,et al. Six cases of aggressive natural killer-cell leukemia in a Chinese population. , 2014, International journal of clinical and experimental pathology.
[27] Y. Kwong,et al. How I treat NK/T-cell lymphomas. , 2013, Blood.
[28] R. Suzuki,et al. Aggressive natural killer cell leukemia: Therapeutic potential of l‐asparaginase and allogeneic hematopoietic stem cell transplantation , 2012, Cancer science.
[29] Takashi Saito,et al. Antitumor activities of valproic acid on Epstein–Barr virus‐associated T and natural killer lymphoma cells , 2012, Cancer science.
[30] N. Jiang,et al. Flow cytometric immunophenotyping is of great value to diagnosis of natural killer cell neoplasms involving bone marrow and peripheral blood , 2012, Annals of Hematology.
[31] K. Sugimoto,et al. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein‐Barr virus infection , 2011, International journal of cancer.
[32] K. Kawa,et al. Clinicopathological analysis of the age‐related differences in patients with Epstein–Barr virus (EBV)‐associated extranasal natural killer (NK)/T‐cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection‐associated lymphoproliferative disorde , 2011, Histopathology.
[33] Hee-Jin Kim,et al. Frequent CD7 antigen loss in aggressive natural killer-cell leukemia: a useful diagnostic marker. , 2009, The Korean journal of laboratory medicine.
[34] E. Jaffe,et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] Y. Ko,et al. Aggressive Natural Killer Cell Leukemia: Is Epstein-Barr Virus Negativity an Indicator of a Favorable Prognosis? , 2009, Acta Haematologica.
[36] K. Ohshima,et al. Proposed categorization of pathological states of EBV‐associated T/natural killer‐cell lymphoproliferative disorder (LPD) in children and young adults: Overlap with chronic active EBV infection and infantile fulminant EBV T‐LPD , 2008, Pathology international.
[37] M. Aricò,et al. HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.
[38] R. Irons,et al. Aggressive Natural Killer Cell Leukemia: Report of a Chinese Series and Review of the Literature , 2007, International journal of hematology.
[39] Y. Nakazawa,et al. Significance of chemokine receptor expression in aggressive NK cell leukemia , 2005, Leukemia.
[40] D. Catovsky,et al. Prolonged treatment response in aggressive natural killer cell leukemia , 2005, Leukemia & lymphoma.
[41] K. Kawa,et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells , 2004, Leukemia.
[42] R. Egeler,et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. , 1997, Medical and pediatric oncology.